Invention Grant
- Patent Title: DLL3 targeting chimeric antigen receptors and binding agents
-
Application No.: US16802822Application Date: 2020-02-27
-
Publication No.: US11673953B2Publication Date: 2023-06-13
- Inventor: Yi Zhang , Thomas John Van Blarcom , Siler Panowski , Silvia K. Tacheva-Grigorova , Barbra Johnson Sasu
- Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
- Applicant Address: US CA South San Francisco
- Assignee: ALLOGENE THERAPEUTICS, INC.,PFIZER INC.
- Current Assignee: ALLOGENE THERAPEUTICS, INC.,PFIZER INC.
- Current Assignee Address: US CA South San Francisco; US NY New York
- Agency: Allogene Therapeutics, Inc.
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00 ; C12N15/63
Abstract:
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
Public/Granted literature
- US20210107979A1 DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS Public/Granted day:2021-04-15
Information query
